ArticleBMC cancer2025
Epidemiology and outcomes associated with brain metastases among patients with metastatic breast cancer - a cohort study in US electronic health record data.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are limited real-world data on the prevalence of brain metastases (BM) in metastatic breast cancer (mBC) across the treatment pathway, especially when stratified by human epidermal growth factor receptor 2-positive (HER2+) or HER2-negative (HER2-) status. The goals of this study were to estimate the prevalence of BM at metastatic diagnosis and at the start of each line of systemic therapy (LOT), and to describe treatment patterns and overall survival (OS) in patients with and without BM.
methodsThis retrospective cohort study included adult patients in the US with mBC diagnosed between January 2013 - May 2020, with known HER2 status from an electronic health record-derived, deidentified database. Patients were followed from mBC diagnosis to last activity date or death. Descriptive statistics were used for BM prevalence, patient characteristics, and treatment patterns. OS was estimated using the Kaplan-Meier method.
resultsOf 12,644 patients with mBC in the database, 1923 (HER2+) and 9693 (HER2-) were included. The prevalence of BM at mBC diagnosis was 12.5% (HER2+) and 1.7% (HER2-). An NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
conclusionsIn this real-world study of patients receiving care in US oncology clinics, the prevalence of BM in patients with mBC increased by LOT, and most were not receiving NCCN Guideline
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.